BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26892612)

  • 21. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.
    Brossart P; Wirths S; Stuhler G; Reichardt VL; Kanz L; Brugger W
    Blood; 2000 Nov; 96(9):3102-8. PubMed ID: 11049990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Mittendorf EA; Clifton GT; Holmes JP; Clive KS; Patil R; Benavides LC; Gates JD; Sears AK; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2012 May; 118(10):2594-602. PubMed ID: 21989902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot trial of vaccination with Carcinoembryonic antigen and Her2/neu peptides in advanced colorectal cancer.
    Lynch KT; Squeo GC; Kane WJ; Meneveau MO; Petroni G; Olson WC; Chianese-Bullock KA; Slingluff CL; Foley EF; Friel CM
    Int J Cancer; 2022 Jan; 150(1):164-173. PubMed ID: 34480368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
    Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
    J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
    Babatz J; Röllig C; Löbel B; Folprecht G; Haack M; Günther H; Köhne CH; Ehninger G; Schmitz M; Bornhäuser M
    Cancer Immunol Immunother; 2006 Mar; 55(3):268-76. PubMed ID: 16034561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
    Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
    Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
    Jackson DO; Trappey FA; Clifton GT; Vreeland TJ; Peace KM; Hale DF; Litton JK; Murray JL; Perez SA; Papamichail M; Mittendorf EA; Peoples GE
    Clin Immunol; 2018 Oct; 195():28-35. PubMed ID: 30025819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.
    Nagorsen D; Keilholz U; Rivoltini L; Schmittel A; Letsch A; Asemissen AM; Berger G; Buhr HJ; Thiel E; Scheibenbogen C
    Cancer Res; 2000 Sep; 60(17):4850-4. PubMed ID: 10987297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
    Chu CS; Boyer J; Schullery DS; Gimotty PA; Gamerman V; Bender J; Levine BL; Coukos G; Rubin SC; Morgan MA; Vonderheide RH; June CH
    Cancer Immunol Immunother; 2012 May; 61(5):629-41. PubMed ID: 22021066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
    Knutson KL; Schiffman K; Disis ML
    J Clin Invest; 2001 Feb; 107(4):477-84. PubMed ID: 11181647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
    Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
    Knutson KL; Block MS; Norton N; Erskine CL; Hobday TJ; Dietz AB; Padley D; Gustafson MP; Puglisi-Knutson D; Mangskau TK; Chumsri S; Dueck AC; Karyampudi L; Wilson G; Degnim AC
    Clin Cancer Res; 2020 Mar; 26(5):1045-1053. PubMed ID: 31757875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
    J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.
    Ramanathan RK; Lee KM; McKolanis J; Hitbold E; Schraut W; Moser AJ; Warnick E; Whiteside T; Osborne J; Kim H; Day R; Troetschel M; Finn OJ
    Cancer Immunol Immunother; 2005 Mar; 54(3):254-64. PubMed ID: 15372205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
    Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A
    Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.